Results 251 to 260 of about 241,504 (343)

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema

open access: yesAllergy, EarlyView.
ABSTRACT Hereditary angioedema (HAE) with C1 inhibitor deficiency is a rare disease characterized by unpredictable episodes of tissue swelling (angioedema), which, in most cases, occur first under the age of 18 years, and entail a significant burden of disease not only for the patients but also for their families.
Henriette Farkas   +128 more
wiley   +1 more source

Improving Vaccine Assessment Pathways and Decision Making in the Polish Immunization Program. [PDF]

open access: yesVaccines (Basel)
Czech M   +12 more
europepmc   +1 more source

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side

open access: yesAllergy, EarlyView.
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm   +9 more
wiley   +1 more source

Reliability of information recorded on the National Immunization Program Information System. [PDF]

open access: yesEpidemiol Serv Saude
Moraes JC   +35 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy